Verona Pharma plc — Director's Dealing 2023

Oct 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-10-20

Reporting Person: ZACCARDELLI DAVID (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-20	Ordinary Shares	A	800000	—	Acquired	17231800	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter.

F3: Consists of (i) 6,711,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 838,980 ADSs); and (ii) 10,519,960 Ordinary Shares underlying 1,314,995 ADSs.